Subconjunctival bevacizumab for corneal neovascularization.
OBJECTIVE
To describe whether subconjunctival bevacizumab decreases corneal neovascularization in patients with ocular surface inflammatory diseases.


METHODS
The study is a retrospective case series that includes 8 eyes of 7 patients with corneal neovascularization. Patients received 1-3 injections of 2.5 mg subconjunctival bevacizumab. Morphologic changes were assessed clinically by the same investigator at each visit.


RESULTS
Subconjunctival bevacizumab was well-tolerated without obvious corneal side effects. All 8 eyes of the 7 patients showed a reduction in the neovascularized area.


CONCLUSIONS
Subconjunctival bevacizumab may provide an additional strategy in improving vision or improving success of corneal grafts in these patients.
Doctor
Priyanka P
PP
Ocular Immunology and Uveitis Foundation, Massachusetts Eye Research and Surgery Institute, Harvard Medical School, Cambridge, MA 02142, USA.
Bhat
Pooja V
PV
Foster
C Stephen
CS
D000293:Adolescent; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003228:Conjunctiva; D016510:Corneal Neovascularization / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D009877:Endophthalmitis / Q000150:complications; D005260:Female; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab